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Abstract: Introduction
Autologous haematopoietic stem cell transplantation (AHSCT) with anti-thymocyte
globulin (ATG) conditioning as treatment of active multiple sclerosis (MS) is rapidly
increasing across Europe (EBMT registry data 2017). Clinically significant Epstein Barr
virus reactivation (EBV-R) following AHSCT with ATG for severe autoimmune
conditions is an under-recognised complication relative to T-cell deplete transplants
performed for haematological diseases. This retrospective study reports EBV-R
associated significant clinical sequelae in MS patients undergoing AHSCT with rabbit
ATG.
Methods
Retrospective data was analysed for 36 consecutive MS-AHSCT patients at Kings
College Hospital, London. All patients routinely underwent weekly EBV DNA PCR
monitoring and serum electrophoresis for monoclonal gammopathy (MG or M-protein).
EBV-R with rising EBV viral load, M-protein and associated clinical sequelae were
captured from clinical records.
Results
All patients had evidence of rising EBV DNA-emia, including 7 who were lost to long
term follow-up, with a number of them developing high EBV viral load & associated
lymphoproliferative disorder (LPD). Nearly 72% (n-18/29) developed de-novo MG,
some with significant neurological consequences with high M-protein and EBV-R. Six
patients required anti-CD20 therapy (rituximab) with complete resolution of EBV related
symptoms. Receiver operating characteristics (ROC) estimated a peak EBV viraemia
of >500,000 DNA copies/ml correlated with high sensitivity (85.5%) & specificity
(82.5%) (AUC-0.87; p-0.004) in predicting EBV-R related significant clinical events.
Conclusion
Symptomatic EBV reactivation increases risk of neurological sequelae and LPD in MS-
AHSCT. We recommend regular monitoring for EBV and serum electrophoresis for MG
be mandated in MS patients in the first 3 months post AHSCT.
Response to Reviewers: To
Dr Barbara D Alexander M.D.
Associate Editor
Clinical Infectious Diseases
Dated: 30th Dec 2018
Dear Dr Alexander
Subject: Response to Reviewers
Manuscript Title:
EBV and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell
Transplantation for Multiple Sclerosis.
We would like to thank the journal for provisionally accepting our work. Considering the
reviewer’s comments, we have made revisions to the manuscript with responses
outlined for each of the queries raised by the reviewer, as below:
The Authors simply must have the manuscript edited for English grammar as many of
the mistakes change the meaning of the sentence.  Some (but not all) of the issues are
as follows:
Response:
Please accept our apologies for the grammatical errors in the manuscript. We have
reviewed and edited these errors where appropriate including the ones highlighted
below.
Line 138 and line 357.  deleted " be mandated".  Cohort is too small to warrant
"mandate"..but your data can lead to recommendation..
Response:
We have edited and replaced the word ‘mandate’ from the phrase.
Line 212-215. Please include the conversion factor for your assay to IU/ml in the
methods section  i.e 10 EBV DNA copies/ml=10 IU/ml
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Response:
This has been rephrased within methods section; line 202-203
line 282: HAS versus  IS?...I think "is"
Response:
Correction made to “is”
Line 298 and 300- not sure systemic sclerosis needs to be capitalized.  But if so, needs
to be so throughout manuscript
Response:
We have edited and removed un-necessary capitalisation for similar errors across the
manuscript.
Lines 309-312.  This sentence is not understandable based on current punctuation.
Please address. ????This is further corroborated by the fact that similar LPD risk has
not been observed in other ADs managed with ATG in our center. For example, among
patients with Crohn' disease treated with ATG-AHSCT and those with severe aplastic
anemia treated with ATG/cyclopsorin, only 52% (x/x) developed EBV-R (unpublished
data) and none had LPD, suggesting that the problem may not be ATG specific.
Response:
Thank you for the suggestion. We have rephrased this to reflect our experience with
other Autoimmune diseases (lines 310-315).
Line 319 delete the words "may still have"
Response:
correction made.
Line 330 seems to "be"?
Response:
correction made.
Line 340 "copies"/ml
Response:
correction made.
Thank you again for your review of the revised manuscript. We hope these revisions
are satisfactory and will allow formal acceptance for publication.
Yours sincerely
On behalf of all co-authors:
Dr Varun Mehra, MRCP(UK), FRCPath               Dr Majid Kazmi; FRCP(UK) FRCPath
Department of Haematological Medicine       Chief of Cancer Division & Consultant
Haematologist
Kings College Hospital, London, UK       Kings, Guy’s & St Thomas’ Hospital, London,
UK
Varun.Mehra@nhs.net ; Ph-004478865087013Majidkazmi@nhs.net; PH-
004478027617716
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To  
Professor Robert Schooley, M.D. 
The Editor-in-Chief 
Clinical Infectious Diseases 
          
Dated:  20th Dec 2018 
 
Dear Professor Schooley (Editor-in-Chief) and Dr Alexander (Associate Editor) 
  
We are pleased to submit our revised article entitled; “EBV & Monoclonal Gammopathy of Clinical 
Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis” for consideration of 
publication in your internationally reputed journal, Clinical Infectious Diseases.  
 
Just to summarise again: Autologous Stem Cell Transplants (AHSCT) with anti-thymocyte globulin ATG) 
based conditioning is a novel approach to treatment of active multiple sclerosis (MS) and recent data 
from MIST study collaborators (Burt et al; Clinical Trial Registry: NCT00273364) have shown some exciting 
preliminary results showing superiority of AHSCT over established disease modifying therapies, 
confirming results from other UK and international studies in this field. However, as the evidence builds, 
safety aspects of these procedures needs to be seriously considered. 
 
This study reports rates of Epstein Barr virus (EBV) reactivation and associated clinical sequelae with 
monoclonal gammopathy (M-protein), in cohort of Multiple Sclerosis patients who underwent ATG 
conditioned immunosuppressive AHSCT in a single centre. We report a significantly higher proportion of 
MS patients had detectable EBV DNA post-AHSCT; were more likely to develop clinically significant EBV 
viraemia of >500,000 DNA copies/ml and develop de-novo M-protein of clinical significance with clinical 
events ranging from probable lymphoproliferative disorders and disabling neurological complications, 
unrelated to MS. This report of significant clinical complications related to EBV and M-protein, possibly 
reflect underlying altered immunopathological state of MS disease and its interactions with reactivation of 
EBV virus, which if monitored and treated pre-emptively may reduce associated morbidity and improve 
outcomes.  
 
To help readers, we have also described two interesting clinical vignettes as a supplementary to this report, 
highlighting significant risk of neurological events following development of M-protein, triggered following 
EBV reactivations in MS patients. 
 
We can confirm that this manuscript has not been published and is not under consideration for publication 
elsewhere. All authors have seen, approved and contributed to this work.  We have no conflicts of interest 
to disclose. We believe that this report fits well within the scope of your journal, highlighting important 
clinical message about EBV complications in ATG conditioned AHSCT for MS and will appeal to journal’s 
readers interested in infectious complications related to immunosuppressive therapies including AHSCTs 
for autoimmune conditions, with a potential to change clinical practice in this area. We have provided point 
to point responses to the reviewer’s comments. 
  
Thank you for your consideration of this revised manuscript and looking forward to your acceptance. 
 
Yours Sincerely 
 
On behalf of all co-authors: 
Dr Varun Mehra, MRCP(UK), FRCPath  Dr Majid Kazmi; FRCP(UK) FRCPath 
Department of Haematological Medicine  Chief of Cancer Division & Consultant Haematologist 
Kings College Hospital, London, UK  Kings, Guy’s & St Thomas’ Hospital, London, UK  
Varun.Mehra@nhs.net ; Ph-004478865087013 Majidkazmi@nhs.net; PH-004478027617716 
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Abstract 81 
Introduction 82 
Autologous haematopoietic stem cell transplantation (AHSCT) with anti-thymocyte globulin 83 
(ATG) conditioning as treatment of active multiple sclerosis (MS) is rapidly increasing 84 
across Europe (EBMT registry data 2017). Clinically significant Epstein Barr virus 85 
reactivation (EBV-R) following AHSCT with ATG for severe autoimmune conditions is an 86 
under-recognised complication relative to T-cell deplete transplants performed for 87 
haematological diseases. This retrospective study reports EBV-R associated significant 88 
clinical sequelae in MS patients undergoing AHSCT with rabbit ATG. 89 
Methods 90 
Retrospective data was analysed for 36 consecutive MS-AHSCT patients at Kings College 91 
Hospital, London. All patients routinely underwent weekly EBV DNA PCR monitoring and 92 
serum electrophoresis for monoclonal gammopathy (MG or M-protein). EBV-R with rising 93 
EBV viral load, M-protein and associated clinical sequelae were captured from clinical 94 
records. 95 
Results 96 
All patients had evidence of rising EBV DNA-emia, including 7 who were lost to long term 97 
follow-up, with a number of them developing high EBV viral load & associated 98 
lymphoproliferative disorder (LPD). Nearly 72% (n-18/29) developed de-novo MG, some 99 
with significant neurological consequences with high M-protein and EBV-R. Six patients 100 
required anti-CD20 therapy (rituximab) with complete resolution of EBV related symptoms. 101 
Receiver operating characteristics (ROC) estimated a peak EBV viraemia of >500,000 DNA 102 
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copies/ml correlated with high sensitivity (85.5%) & specificity (82.5%) (AUC-0.87; p-0.004) 103 
in predicting EBV-R related significant clinical events.  104 
Conclusion 105 
Symptomatic EBV reactivation increases risk of neurological sequelae and LPD in MS-106 
AHSCT. We recommend regular monitoring for EBV and serum electrophoresis for MG in 107 
MS patients in the first 3 months post AHSCT 108 
Key Words: 109 
Multiple Sclerosis; Autologous Hematopoietic Stem Cell Transplantation, Epstein-110 
Barr Virus Infection; Monoclonal Gammopathy; Post-transplant Lymphoproliferative 111 
Disorder 112 
 113 
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INTRODUCTION: 120 
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of 121 
the central nervous system[1]-[2], with  a relapsing-remitting (RRMS) presentation in the 122 
majority of patients at diagnosis.  Recovery from relapses may be complete or partial[3],[4]. 123 
After a variable period of time, people with RRMS may develop a more progressive 124 
disability accumulation with or without superimposed relapses; termed secondary 125 
progressive multiple sclerosis (SPMS). A minority experience progressive disability from the 126 
onset of disease, termed primary progressive multiple sclerosis (PPMS)[4]. A number of 127 
immunomodulatory disease modifying therapies (DMTs) are currently licensed for treatment 128 
of RRMS with an aim of reducing number of relapses and accrual of disability, although with 129 
variable efficacy[5]. Since 1996, Autologous Hematopoietic Stem Cell Transplantation 130 
(AHSCT) has been a novel approach for MS management, using immunoablation followed 131 
by immunomodulation mechanisms, with evidence of significant suppression of 132 
inflammatory activity and qualitative changes in the reconstituted immune system (immune 133 
reset theory)[6–8]. AHSCT appears most effective for MS patients with evidence of 134 
inflammatory activity on MRI, younger age, a shorter disease duration, low to moderate 135 
disability levels (Expanded Disability Status Scale [EDSS] <6 or up to 6.5 if recent 136 
progression) and failure of at least 1 highly active DMT (natalizumab or alemtuzumab) with 137 
no significant comorbidities[9–11]. Recently reported preliminary results of randomised 138 
MIST study[12] found AHSCT to be superior to standard  disease modifying therapy (DMT) 139 
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for RRMS with respect to both treatment failure and disability progression. 140 
 141 
However, risk of subsequent rise in opportunistic infections following such 142 
immunosuppressive therapies remain a potential concern[13]. MS patients undergoing 143 
AHSCT have often been exposed to a number of immunomodulating DMTs; the addition of 144 
immunosuppressive rabbit anti-thymocyte globulin (rATG) to their conditioning regimen may 145 
confer a higher risk of viral reactivation in these patients. The number of AHSCTs 146 
performed for MS is rising significantly in Europe[14] and as more centres perform AHSCT 147 
for this indication, it is increasingly important to recognise the unique problems faced by 148 
these patients post AHSCT. This retrospective study reports for the first time, EBV-R 149 
associated neurological sequelae and lymphoproliferative disorder (LPD) in MS patients 150 
undergoing rATG conditioned AHSCT in our centre. 151 
 152 
METHODS 153 
Patients and procedures 154 
Data was collected retrospectively on 36 consecutive MS patients undergoing AHSCT 155 
between February 2012 and February 2017 at Kings College Hospital, London. Peripheral 156 
blood stem cells were collected following standard mobilisation strategy consisting of 157 
cyclophosphamide 4g/m2 over 2 days and granulocyte colony-stimulating factor for 7 days. 158 
Thirty-five (97%) patients were conditioned using standard protocol of cyclophosphamide 159 
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(50mg/kg for 4 days) and rATG (2.5mg/kg/day for 3 days) for in-vivo lymphodepletion 160 
followed by stem cell infusion. One patient was conditioned with 161 
carmustine/etoposide/cytarabine/melphalan regimen along with an equivalent dose of rATG 162 
(BEAM-ATG) prior to stem cell infusion. The median CD34 stem cell dose returned was 163 
7.17 x10^6/kg (range 4.0-17.1x10^6/kg).  164 
 165 
Prior exposure to EBV was assessed by serological evidence (EBV viral capsid antigen; 166 
VCA IgG).  EBV DNA load monitoring was performed on whole blood samples by 167 
standardised quantitative real-time polymerase chain reaction (RT-PCR) using Rotor-168 
GeneTM (Qiagen) assay of EBV BZLF1 DNA. This assay was adapted from our published 169 
assay using LightCycler (Roche)[15] and since been validated against the recently 170 
published WHO standard, with our lab’s EBV DNA quantification of 10 copies/ml considered 171 
equivalent to 10 IU/ml DNA reported with the WHO reference method[16]. EBV-R was 172 
defined as rising EBV DNA load of >10 copies/millilitre (ml) detected on two consecutive 173 
tests based on our assay sensitivity. Symptomatic EBV-R was captured by peak blood EBV 174 
DNA load, presence of B symptoms (defined by presence of either unexplained weight loss, 175 
recurrent fever, night sweats); which was in-turn defined by clinical, radiological and/or 176 
histological evidence based on recent ECIL-6 guidelines[17]. In addition, significant ‘clinical 177 
events’ were also defined as new & persistent organ dysfunction (e.g. neurological events) 178 
temporally associated with rising EBV viraemia in MS patients. Serum protein 179 
electrophoresis was routinely tested around 3 months post HSCT as part of our institutional 180 
practice, with immunoglobulin subclasses identified by immunofixation electrophoresis. 181 
Patient outcomes were assessed at last follow up as of April 2017.  182 
 183 
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Statistics 184 
The database of transplants and outcomes was built in Microsoft Excel 2016 and statistical 185 
analyses were performed using IBM SPSS Statistics version 24.0. Patient characteristics 186 
are presented as medians (with inter-quartile ranges; IQR) for data with non-normal 187 
distribution. Comparisons of baseline characteristics used Mann-Whitney U test, Fisher’s 188 
exact test, or Chi-squared test for trend as appropriate. Receiver Operating characteristics 189 
(ROC) curve was obtained correlating LPD and clonal gammopathy associated clinical 190 
events with rising EBV viraemia (copies/ml). 191 
 192 
RESULTS 193 
Baseline characteristics are presented in Table 1.  Most MS patients (88.9%) had RRMS 194 
phenotype with median of 2 (range 0-3) DMTs prior to AHSCT. Twenty-two MS patients 195 
had prior exposure to natalizumab and 7 were treated with Alemtuzumab (6 patients 196 
received both). All 36 (100%) MS patients were serologically positive for EBV VCA IgG pre-197 
treatment, indicating prior EBV exposure and had detectable EBV DNA post-AHSCT. 198 
Seven MS patients were lost to long-term follow up for EBV monitoring.  The median time to 199 
first EBV DNA detection post-transplant was 30 days (IQR 23-46 days). EBV DNA levels 200 
peaked at a median of 32 days post-transplant (IQR 31-53 days). All MS patients had 201 
normal baseline lymphocyte counts (median) pre-HSCT with a median time of 46 days 202 
(range 14-404 days) to lymphocyte recovery (defined by total lymphocyte count 203 
>1.0x106/ml) following AHSCT (See Figure 1). A high proportion (86%; n-25/29) of the MS 204 
patients in active follow-up recovered lymphocyte counts around D56 with a median 205 
  
- 9 - 
lymphocyte count of 1.56 (106 cells/ml); Four patients remained lymphopenic at last follow 206 
up. 207 
 208 
All patients were stratified into following 3 groups according to peak rise/burden of EBV 209 
DNA-aemia (copies/ml): <100,000 (<100k) copies/ml, 100,001-500,00 (100k-500k) 210 
copies/ml and >500,000 (>500k) copies/ml to identify any specific thresholds for clinically 211 
significant events related to rising EBV-R (Table 1). The majority of patients (76%) with 212 
rising EBV viral load >100k copies/ml were routinely screened by computed tomographic 213 
(CT) scans to assess for evidence of LPD, in line with our institutional policy. One third 214 
(34.5%) of patients developed peak EBV viraemia of >500k copies/ml. Eight patients 215 
(27.6%) developed symptomatic EBV-R; defined as persistent fever, lymphadenopathy 216 
and/or B symptoms. Of these 8 patients, only 1 (12.5%) had a peak EBV viraemia 217 
<100kDNA copies/ml with the remaining 7 (87.5%) patients having a peak EBV viraemia of 218 
>500k copies/ml.  Three patients with rising EBV viraemia >500k copies/ml had findings 219 
consistent with probable LPD on CT imaging; however, none had definitive histological 220 
diagnosis. Three MS patients had worsening neurological symptoms concurrent with rising 221 
EBV viraemia >500k copies/ml and clonal gammopathy, as described below. 222 
 223 
Interestingly, we also observed frequent de novo monoclonal gammopathy (MG or M-224 
protein) in 18 MS patients (62.4%) following rising EBV viraemia; the majority (n-16) of 225 
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whom developed IgG subtype and the remaining 2 developed IgA and IgM M-protein. 226 
Concerningly two of these patients developed clinically significant M-Protein burden; one 227 
patient with IgG Kappa M-protein of 45.6g/L developed hyper-viscosity and neurological 228 
symptoms mimicking MS relapse, requiring plasma exchange. Another patient developed 229 
significant lumbosacral radiculopathy with rising EBV-R and high IgM lambda M-protein 230 
(IgM 48.5g/L) (see supplementary case vignettes). Figure 2 highlights the association of 231 
neurological symptom onset following rising EBV viraemia (log copies), falling lymphocyte 232 
counts (x 106/ml) with significant rise in M-protein (gm/lt) levels post AHSCT. A third patient 233 
developed painful lower limb paraesthesia following rising EBV viraemia >500k copies/ml, 234 
although did not have any M-protein detected. Their symptoms persisted at last follow up 235 
despite no evidence of MS related new disease activity. 236 
 237 
Six patients were treated with anti-CD20 antibody, rituximab (375mg/m2 weekly up to 4 238 
weeks), due to clinical severity of EBV reactivations and leading to reduction in EBV viral 239 
load and concurrent improvement/resolution of EBV related symptoms. ROC curve analysis 240 
(Figure 3) confirmed EBV viraemia of >500k copies/ml correlated with high sensitivity 241 
(85.5%) and specificity (82.5%) (AUC-0.87; 95%CI-0.73-1.0; p-0.004) in predicting 242 
significant EBV related clinical events (evidence of LPD and/or neurological symptoms) that 243 
may require treatment with rituximab. The sensitivity dropped significantly on lower 244 
estimates for events below 500k copies/ml. 245 
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 246 
The median time to resolution of EBV viraemia post-rituximab was 21 days (IQR 19-124 247 
days) in 5 patients with >500k copies/ml (one patient was treated for late onset persistent 248 
symptomatic clonal gammopathy, despite fall in EBV levels). No significant adverse events 249 
were noted in the treated group. Nine patients had a persistent low level EBV viraemia 250 
detectable at last follow up. All patients who underwent AHSCT were alive as of April 2017.  251 
 252 
DISCUSSION: 253 
MS as an autoimmune disorder (AD) is theorised to have generally similar underlying 254 
pathophysiological immune dysregulation mechanisms[18–22] relative to other chronic 255 
autoimmune conditions. Epstein-Barr virus (EBV) is increasingly implicated in the 256 
pathogenesis of MS by virtue of epidemiological and serological evidence, impaired CD8+ 257 
T cell immune responses to EBV and possible underlying genetic susceptibility for 258 
autoimmunity (with EBV encoded protein interactions), as recently described by Harley et al 259 
and others[1,23–25].  260 
 261 
Generally, EBV-R related LPD has been reported in both allogeneic (allo-HSCT) and solid 262 
organ transplants treated with immunosuppressive therapy, often with a significant impact  263 
on organ function and overall survival[26–30]. It is observed that reduced intensity allo-264 
HSCT for malignant haematological conditions using alemtuzumab have a relatively lower 265 
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overall risk of LPD compared to ATG based treatments, possibly mediated by more 266 
effective pan-B & T cell lymphodepletion. In contrast, ATG primarily affects the T-cell 267 
repertoire with delayed EBV specific CD8+ T cell recovery[31]. Clinically significant 268 
endogenous viral infections including EBV following ATG conditioned AHSCT for severe 269 
ADs  such as Crohn’s disease and systemic sclerosis is increasingly recognised, but the 270 
development of lymphoproliferative disorders (LPD) remains rare in these ADs[13,32,33].  271 
Nash et al[32] concerningly reported 2 deaths (1 MS and 1 systemic sclerosis patient) from 272 
EBV related LPD in 56 ATG conditioned AHSCT for autoimmune diseases. Additionally, 273 
EBV associated haemophagocytosis in ATG-AHSCT for ADs have also been reported[34], 274 
with one resulting in death of the patient[35].  275 
 276 
Our report of suspected EBV related LPDs (~10%) in MS-AHSCT group is relatively higher 277 
than published reports with allo-HSCTs (4.5-7%)[36,37] and our own centre’s unpublished 278 
T-cell depleted allo-HSCT experience (6.5%); possibly a reflection of underlying 279 
immunopathological state of MS itself[38]. This is further corroborated by the fact that 280 
similar LPD risk has not been observed in other ADs, e.g. Crohn’s disease, treated with 281 
ATG -AHSCT in this centre. Another example from our centre’s experience of severe 282 
aplastic anaemia (n-40) treated with ATG/ciclosporin, only 52% (n-21/40) developed EBV-R 283 
(unpublished data) and none had LPD or required any treatment, suggesting that the 284 
problem may not be ATG specific. 285 
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 286 
Our study’s observation of significant persistent neurological events (with no evidence of 287 
new MS disease activity) associated with clonal gammopathy suggest a potentially new 288 
clinical syndrome, described for the first time in ATG conditioned AHSCTs in MS and 289 
possibly induced by clonal B cell dysregulation following EBV-R. It could be hypothesised 290 
that any remaining EBV infected latent B cells, surviving despite high doses of 291 
cyclophosphamide (given with mobilisation and conditioning in MS ASHCT)[8] and 292 
compounded by depletion of CD8+ T cells by ATG, may serve as potential source for EBV 293 
escape while interacting abnormally within the host immune micro-environment[39] and 294 
leading to rise in M-protein, LPD and neuro-inflammatory insults in some of the MS patients 295 
post AHSCT. Reports of lower incidence of EBV-R and LPD in another commonly used 296 
protocol for MS-AHSCT using BEAM-ATG (Ricardo Saccardi, Carregi University Hospital, 297 
Florence; personal communication) may reflect the greater myeloablative effect of BEAM 298 
chemotherapy which could further deplete the residual B cell pool and thus lower potential 299 
for EBV proliferation. It is plausible that dose of rATG is critical, given we have not seen 300 
similar reports from other centres where less rATG doses were given for MS-AHSCT (range 301 
between 5.0-6.5 mg/Kg; personal communication) but there seems to be some variability in 302 
prospective serial EBV monitoring in these patients. 303 
 304 
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The clinical threshold for EBV viral load as a significant risk factor for post-transplant LPD is 305 
widely debated. This study reports peak EBV viral load >500k copies/ml post AHSCT is 306 
significantly associated with probable LPD and neurological events in MS patients with high 307 
sensitivity (85.5%) and specificity (82.5%) (p-0.004) (Fig 3, ROC curve). Our ROC curve 308 
estimates are potentially limited by the relatively small number of events analysed but this 309 
has consistently been useful in our MS-AHSCT experience for predicting clinical events 310 
with high EBV load. Our EBV PCR assay has been validated against the recently defined 311 
standard WHO reference method (i.e. 10 copies/ml=10 IU/ml EBV DNA) [16] and thus this 312 
EBV threshold for pre-emptive treatment with Rituximab, can potentially be applied in 313 
relevant clinical context in other centres using similar validated essays. Rituximab treatment 314 
delivered good overall response in our symptomatic patients, with resolution of EBV related 315 
clinical symptoms and no subsequent viral or bacterial infections at last follow up. The role 316 
of prophylactic or pre-transplant rituximab in MS-AHSCT is also a potential area of interest 317 
in reducing risk of EBV-LPD in stem cell transplants as observed by Burns et al[36] and 318 
future randomised studies are required to investigate its potential benefit. 319 
 320 
Our study limitations include its retrospective nature and that no suspected LPD patients 321 
had histological confirmation, mainly related to patient refusal or technical difficulties. Seven 322 
MS patients were lost to follow up for EBV monitoring following discharge, which limits the 323 
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findings of this study. Additionally, our numbers were too small to identify any association of 324 
EBV related clinical events with previous DMT exposure in MS patients. 325 
 326 
In conclusion, symptomatic EBV reactivation increases risk of neurological sequelae and 327 
LPD in MS-AHSCT. Regular monitoring for rising EBV viraemia, as recommended by 328 
Snowden et al [10] and Muraro et al [11], and serum electrophoresis for M-protein should 329 
be considered in the  first 3 months post-AHSCT for MS. We recommend persistent high 330 
EBV viraemia > 500k DNA copies/ml as potential trigger for consideration of pre-emptive 331 
anti-CD20 therapy and potentially reduce associated morbidity.  332 
 333 
 334 
 335 
 336 
 337 
 338 
  339 
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Table 1: Baseline patient characteristics and EBV related clinical events according to peak 520 
EBV DNA-aemia burden.  521 
 522 
Baseline characteristics (n-36) 
 
Patient Groups 
according to peak 
EBV DNA in 
copies/ml  
(n-29) 
0 - 100,000 
100,001 
- 
500,000 
>500,000 
Median age at time of AHSCT in years 
(range) 
43.5 
(36– 47) 
No of patients (%) 16 (55.2) 3 (10.3) 10 (34.5) 
Gender 
Male 
Female 
 
19 (52.8%) 
17 (47.2%) 
M-Protein (n) 11 0 7 
Disease Type (n; %) 
Relapsing Remitting MS 
Secondary Progressive MS 
Primary Progressive MS 
 
22 (61.1%) 
10 (27.8%) 
4 (11.1%) 
Median EBV DNA 
log value at peak 
(IQR) 
4.8 
(3.5-4.8) 
5.5 
(N/A) 
6.25 
(6.1-6.9) 
Median number of previous DMT 
(range) 
2 (0 – 6) 
Median number of 
prior DMTs 
2 3 2 
Previous use of high efficacy DMT (n) 
Natalizumab 
Alemtuzumab 
Both 
 
22 
8 
6 
Symptomatic EBV 
(n) 
1 0 7 
Median EDSS (range) 
6.0 
(2.5 – 8.0) 
LPD diagnosis 
(CT/Biopsy) (n) 
0 0 
3 
by CT alone 
Median follow up post AHSCT in days 
(range) 
436 
(188 – 785) 
Neuro/autoimmune 
complications (n) 
0 0 3 
No. of patients with prior EBV 
exposure (n; %) 
36 (100%) 
Treated with 
Rituximab (n) 
0 0 6 
No. of patients with detectable EBV 
post AHSCT (n; %) 
29 (80.5%) 
Confirmed EBV 
resolution at last 
follow up (n) 
7 2 7 
No. of patients lost to long term follow 
up (n; %) 
7 (19.5%) 
Detectable EBV DNA 
at last follow up (n) 
9 1 3 
Median Time to EBV detection post 
AHSCT in days (IQR) 
30 (23-46) 
Median time for EBV 
resolution (IQR in 
days) 
67 days 
(44-155) 
47 days 
(N/A) 
63 days 
(45 - 170) 
Median Time to peak EBV DNA levels 
in days (IQR) 
32 (31-53) 
Median Time to peak 
EBV DNA levels in 
days (IQR) 
40 days 
(25-85) 
30 days 
(N/A) 
39 days 
(32-43) 
 523 
Abbreviations: 524 
AHSCT- Autologous Haematopoietic Stem cell transplant; CT- computed tomography; 525 
DMT- Disease modifying therapy; EBV- Epstein Barr virus; EDSS- Kurtzke Expanded 526 
Disability Status Scale; IQR- Interquartile range; LPD- Lymphoproliferative disease; M-527 
Protein: Monoclonal paraprotein or gammopathy; MS- Multiple Sclerosis 528 
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Figure Legends 529 
 530 
Figure 1: Trend of Lymphocyte count recovery following ATG in MS patients. 531 
 532 
Legend: This figure shows trends of lymphocyte count from baseline to recovery post 533 
AHSCT for MS patients. Majority of patients had normal baseline lymphocyte counts pre-534 
HSCT and became lymphopenic post ATG with counts recovering towards d+28 and >85% 535 
of patients recovered counts by d+56, with some overshooting from their baseline, possibly 536 
reflective of EBV related lymphoproliferation in some of these patients.  537 
 538 
AHSCT: Autologous Haematopoietic Stem Cell Transplantation; ATG: Anti-Thymocyte 539 
Globulin; d+: Days post AHSCT; MS: Multiple Sclerosis. 540 
 541 
 542 
Figure 2: Paraprotein, EBV & Lymphocyte trends in two MS patients with significant 543 
neurological sequelae post AHSCT. 544 
 545 
Legend: This figure demonstrates trends of EBV copies (log), paraprotein levels (g/lt) and 546 
Lymphocyte levels (counts x10^6/ml) in two MS patients with significant neurological 547 
symptoms following EBV reactivation. Both patients had significant EBV viraemia (log>5.2 548 
or >500,000 copy number) and developed significant paraproteinaemia, which was only 549 
noted after persistent unexplained neurological symptoms. The trend reversed following 550 
anti-CD20 (rituximab) therapy, with limited recovery in neurological symptoms. 551 
 552 
D: Days post AHSCT; EBV-R: Epstein Barr Virus reactivation; MS: Multiple sclerosis; 553 
AHSCT: Autologous Haematopoietic Stem Cell Transplants. 554 
 555 
 556 
Figure 3: ROC curve estimates for peak EBV viraemia levels and significant clinical 557 
events in MS post AHSCT. 558 
 559 
Legend: ROC curve demonstrating significant correlation between high EBV levels and 560 
clinical events (LPD & neurological events) in MS-AHSCT patients, with highest sensitivity 561 
and specificity noted with peak EBV viraemia of >500,000 copies/ml (p-0.0004). 562 
 563 
EBV: Epstein Barr Virus; LPD- Lymphoproliferative disorder; MS-AHSCT: Multiple Sclerosis 564 
patients treated with autologous haematopoietic stem cell transplants; ROC: receiver 565 
operating characteristics 566 
 567 
 568 
 569 
 570 
 571 
 572 
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 EBV and Monoclonal Gammopathy of Clinical Significance in Autologous 
Stem Cell Transplantation for Multiple Sclerosis. 
Running Title: EBV complications in Auto-HSCT for MS 
SUPPLEMENTARY: 
Case vignettes of 2 MS patients describing EBV-related significant paraproteinaemia 
and neurological sequelae. 
 
Patient 1 
43-year-old female with Relapsing Remitting Multiple Sclerosis (RRMS), previously treated 
with natalizumab and three courses of alemtuzumab but continued to have breakthrough 
disease. She had a relatively mild baseline disability with an Expanded Disability Severity 
Scale (EDSS) of 2.5. She had an uncomplicated inpatient stay for the Autologous 
Haematopoeitic Stem cell transplant (AHSCT) procedure and was discharged on day 15 post-
transplant.  A blood test on day 26 demonstrated Epstein-Barr Virus (EBV) reactivation 
(155,845 copies/ml). A repeat test on day 34 showed an increase in copy number to 638,634 
copies/ml. She was asymptomatic, and the plan was to monitor this closely. On day 37 post-
transplant she developed a significant deterioration in strength in the right lower limb and on 
day 42 she developed pyrexia and was admitted to a local hospital. She was found to have 
CMV reactivation which was treated with IV ganciclovir as well as ongoing EBV reactivation 
and she remained an inpatient for 4 weeks.  She did not receive rituximab at the local centre 
but on repeat testing at day 145 the copy number was vastly reduced at 2,355 copies/ml. A 
high IgM paraproteinaemia was first detected at day 92 post-transplant (48.58g/L). This had 
not been routinely monitored previously. This paraproteinaemia was initially felt to be 
asymptomatic and was monitored closely, slowly improving over time. A CT scan was 
performed which demonstrated a single 1.7cm right hilar lymph node requiring observation.  
Supplemental -Case Vignettes Click here to access/download;Supplemental data/Appendix -
published online only;SUPPLEMENTARY-MS EBV updated
A bone marrow aspirate showed a small excess of plasma cells (5-9%) on aspirate with no 
other significant findings.  
 
The EBV reactivation initially settled at 6 months post-transplant. At one-year post transplant 
she had a persistent IgM paraprotein (23g/L) and her right leg weakness had continued to 
progress with her EDSS now at 5.0. There was also a mild recurrence of EBV (DNA at 1,335 
copies/ml). It was considered that as the onset of the right leg weakness had coincided with 
the high level of EBV reactivation and paraproteinaemia that these factors may have driven a 
peripheral neuropathy. She was treated with rituximab 375mg/m2 weekly for 4 weeks at 19 
months post-transplant following which EBV DNA again became undetectable and the 
paraprotein reduced to 9g/L. Despite this, there was no improvement in strength of the right 
leg. Nerve conduction studies subsequently confirmed an L5-S1 radiculopathy but without a 
generalised polyneuropathy neuropathy. She has had no new or active demyelinating lesions 
on MRI head and spine post-transplant that would account for these symptoms and the slowly 
progressive nature of the weakness does not suggest an MS relapse.  The cause of the 
weakness is likely an atypical IgM paraprotein associated radiculo-neuropathy was strongly 
suspected. 
 
Patient 2 
42-year-old male with Secondary Progressive Multiple Sclerosis (SPMS), previously treated 
with interferon and copaxone which were discontinued due to side effects and ongoing 
relapses, respectively. He was then treated with natalizumab for 2 years but continued to 
progress and was offered HSCT. He had a moderate level of baseline disability with an EDSS 
of 5.5 (walking at least 100m unaided). The transplant procedure was complicated by 
neutropenic sepsis which was treated successfully, and he was discharged on day 13 post-
transplant with no new neurological symptoms.  He was readmitted on day 17 post-transplant 
with pyrexia and rigors. Blood cultures grew Stenotrophomonas maltophilia and he was 
treated for line sepsis with appropriate antibiotics and fully recovered. An EBV viraemia of 
58,324 copies/ml was detected for the first time on this admission. On day 22 he had 
developed new urinary urgency, diplopia and significant deterioration in mobility. This was felt 
to represent either a pseudorelapse driven by infection or a true relapse and an MRI was 
performed which demonstrated no new demyelinating lesions and no other significant 
pathology. A repeat EBV DNA assessment on day 28 demonstrated a significant rise in EBV 
viraemia to >10 million copies/ml (log change).  
 
His neurological symptoms persisted and on day 34 he began spiking temperatures again; 
antibiotics were restarted but blood and urine cultures came back negative, but his EBV 
viraemia had risen to over 39 million copies/ml.  He continued to experience intermittent 
pyrexia, which possibly was attributed to his EBV viraemia. No evidence of lymphadenopathy 
was noted during this period. Due to significant neurological decline, he was consequently 
commenced on rituximab 375mg/m2 weekly for 4 weeks on day 38 post-transplant. Testing on 
day 51 demonstrated a reduction in EBV viraemia to DNA of 2.2 million copies/ml and on day 
52, a significant IgG kappa paraproteinaemia (45.6 g/L) was identified.  This had not been 
routinely monitored previously. It was considered that this degree of paraproteinemia and 
resulting hyperviscosity may have been a driver of his neurological symptoms. These values 
continued to improve over time with further doses of rituximab and the EBV vireamia was 
<100,000 copies/ml and the IgG kappa paraprotein down to 8.63 g/L by Day 87. However, 
due to persistence of these markers as well as his ongoing neurological symptoms, he was 
given a single plasma exchange on day 80 that was of minimal symptomatic benefit.  
 
He had ongoing rehabilitation, including a short admission in a specialist neuro-rehabilitation 
ward. neurorehabilitation unit. At one year review he still required bilateral support to walk, 
putting his EDSS at 6.5. A repeat MRI at 12 months post-transplant was again stable with no 
new demyelinating lesions. This patient demonstrated significant deterioration in his condition 
post-transplant and although there may be an element of disease progression, we suspect 
this was in large part driven by EBV viraemia and associated paraproteinaemia/hyperviscosity. 
The EBV viraemia was undetectable at the last follow up, although there was ongoing 
paraproteinaemia with an IgG kappa of 15 g/L. 
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Abstract 111 
Introduction 112 
Autologous haematopoietic stem cell transplantation (AHSCT) with anti-thymocyte globulin 113 
(ATG) conditioning as treatment of active multiple sclerosis (MS) is rapidly increasing across 114 
Europe (EBMT registry data 2017). Clinically significant Epstein Barr virus reactivation (EBV-115 
R) following AHSCT with ATG for severe autoimmune conditions is an under-recognised 116 
complication relative to T-cell deplete transplants performed for haematological diseases. 117 
This retrospective study reports EBV-R associated significant clinical sequelae in MS patients 118 
undergoing AHSCT with rabbit ATG. 119 
Methods 120 
Retrospective data was analysed for 36 consecutive MS-AHSCT patients at Kings College 121 
Hospital, London. All patients routinely underwent weekly EBV DNA PCR monitoring and 122 
serum electrophoresis for monoclonal gammopathy (MG or M-protein). EBV-R with rising 123 
EBV viral load, M-protein and associated clinical sequelae were captured from clinical 124 
records. 125 
Results 126 
All patients had evidence of rising EBV DNA-emia, including 7 who were lost to long term 127 
follow-up, with a number of them developing high EBV viral load & associated 128 
lymphoproliferative disorder (LPD). Nearly 72% (n-18/29) developed de-novo MG, some with 129 
significant neurological consequences with high M-protein and EBV-R. Six patients required 130 
anti-CD20 therapy (rituximab) with complete resolution of EBV related symptoms. Receiver 131 
operating characteristics (ROC) estimated a peak EBV viraemia of >500,000 DNA copies/ml 132 
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correlated with high sensitivity (85.5%) & specificity (82.5%) (AUC-0.87; p-0.004) in 133 
predicting EBV-R related significant clinical events.  134 
Conclusion 135 
Symptomatic EBV reactivation increases risk of neurological sequelae and LPD in MS-136 
AHSCT. We recommend regular monitoring for EBV and serum electrophoresis for MG be 137 
mandated in MS patients in the first 3 months post AHSCT 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
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INTRODUCTION: 151 
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of the 152 
central nervous system[1]-[2], with  a relapsing-remitting (RRMS) presentation in the majority 153 
of patients at diagnosis.  Recovery from relapses may be complete or partial[3],[4]. After a 154 
variable period of time, people with RRMS may develop a more progressive disability 155 
accumulation with or without superimposed relapses; termed secondary progressive multiple 156 
sclerosis (SPMS). A minority experience progressive disability from the onset of disease, 157 
termed primary progressive multiple sclerosis (PPMS)[4]. A number of immunomodulatory 158 
disease modifying therapies (DMTs) are currently licensed for treatment of RRMS with an 159 
aim of reducing number of relapses and accrual of disability, although with variable 160 
efficacy[5]. Since 1996, Autologous Hematopoietic Stem Cell Transplantation (AHSCT) has 161 
been a novel approach for MS management, using immunoablation followed by 162 
immunomodulation mechanisms, with evidence of significant suppression of inflammatory 163 
activity and qualitative changes in the reconstituted immune system (immune reset theory)[6–164 
8]. AHSCT appears most effective for MS patients with evidence of inflammatory activity on 165 
MRI, younger age, a shorter disease duration, low to moderate disability levels (Expanded 166 
Disability Status Scale [EDSS] <6 or up to 6.5 if recent progression) and failure of at least 1 167 
highly active DMT (natalizumab or alemtuzumab) with no significant comorbidities[9–11]. 168 
Recently reported preliminary results of randomised MIST study[12] found AHSCT to be 169 
superior to standard  disease modifying therapy (DMT) for RRMS with respect to both 170 
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treatment failure and disability progression. 171 
 172 
However, risk of subsequent rise in opportunistic infections following such 173 
immunosuppressive therapies remain a potential concern[13]. MS patients undergoing 174 
AHSCT have often been exposed to a number of immunomodulating DMTs; the addition of 175 
immunosuppressive rabbit anti-thymocyte globulin (rATG) to their conditioning regimen may 176 
confer a higher risk of viral reactivation in these patients. The number of AHSCTs performed 177 
for MS is rising significantly in Europe[14] and as more centres perform AHSCT for this 178 
indication, it is increasingly important to recognise the unique problems faced by these 179 
patients post AHSCT. This retrospective study reports for the first time, EBV-R associated 180 
neurological sequelae and lymphoproliferative disorder (LPD) in MS patients undergoing 181 
rATG conditioned AHSCT in our centre. 182 
 183 
METHODS 184 
Patients and procedures 185 
Data was collected retrospectively on 36 consecutive MS patients undergoing AHSCT 186 
between February 2012 and February 2017 at Kings College Hospital, London. Peripheral 187 
blood stem cells were collected following standard mobilisation strategy consisting of 188 
cyclophosphamide 4g/m2 over 2 days and granulocyte colony-stimulating factor for 7 days. 189 
Thirty-five (97%) patients were conditioned using standard protocol of cyclophosphamide 190 
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(50mg/kg for 4 days) and rATG (2.5mg/kg/day for 3 days) for in-vivo lymphodepletion, 191 
followed by stem cell infusion. One patient was conditioned with 192 
carmustine/etoposide/cytarabine/melphalan regimen along with an equivalent dose of rATG 193 
(BEAM-ATG) prior to stem cell infusion. The median CD34 stem cell dose returned was 7.17 194 
x10^6/kg (range 4.0-17.1x10^6/kg).  195 
 196 
Prior exposure to EBV was assessed by serological evidence (EBV viral capsid antigen; VCA 197 
IgG).  EBV DNA load monitoring was performed on whole blood samples by standardised 198 
quantitative real-time polymerase chain reaction (RT-PCR) using Rotor-GeneTM (Qiagen) 199 
assay of EBV BZLF1 DNA. This assay was, adapted from our published assay using 200 
LightCycler (Roche)[15] and since been validated against the recently published WHO 201 
standard, with our lab’s EBV DNA quantification of 10 copies/ml considered equivalent to 10 202 
IU/ml DNA reported with the WHO reference method[16]. .EBV-R was defined as rising EBV 203 
DNA load of >10 copies/millilitre (ml) detected on two consecutive tests based on our assay 204 
sensitivity. Symptomatic EBV-R was captured by peak blood EBV DNA load, presence of B 205 
symptoms (defined by presence of either unexplained weight loss, recurrent fever, night 206 
sweats); which was in-turn defined by clinical, radiological and/or histological evidence based 207 
on recent ECIL-6 guidelines[17]. In addition, significant ‘clinical events’ were also defined as 208 
new & persistent organ dysfunction (e.g. neurological events) temporally associated with 209 
rising EBV viraemia in MS patients. Serum protein electrophoresis was routinely tested 210 
around 3 months post HSCT, as part of our institutional practice, with immunoglobulin 211 
subclasses identified by immunofixation electrophoresis. Patient outcomes were assessed at 212 
last follow up as of April 2017.  213 
 214 
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Statistics 215 
The database of transplants and outcomes was built in Microsoft Excel 2016 and statistical 216 
analyses were performed using IBM SPSS Statistics version 24.0. Patient characteristics are 217 
presented as medians (with inter-quartile ranges; IQR) for data with non-normal distribution. 218 
Comparisons of baseline characteristics used Mann-Whitney U test, Fisher’s exact test, or 219 
Chi-squared test for trend as appropriate. Receiver Operating characteristics (ROC) curve 220 
was obtained correlating LPD and clonal gammopathy associated clinical events with rising 221 
EBV viraemia (copies/ml). 222 
 223 
RESULTS 224 
Baseline characteristics are presented in Table 1.  Most MS patients (88.9%) had RRMS 225 
phenotype with median of 2 (range 0-3) DMTs prior to AHSCT. Twenty-two MS patients had 226 
prior exposure to natalizumab and 7 were treated with Alemtuzumab (6 patients received 227 
both). All 36 (100%) MS patients were serologically positive for EBV VCA IgG pre-treatment, 228 
indicating prior EBV exposure and had detectable EBV DNA post-AHSCT. Seven MS 229 
patients were lost to long-term follow up for EBV monitoring.  The median time to first EBV 230 
DNA detection post-transplant was 30 days (IQR 23-46 days). EBV DNA levels peaked at a 231 
median of 32 days post-transplant (IQR 31-53 days). All MS patients had normal baseline 232 
lymphocyte counts (median) pre-HSCT with a median time of 46 days (range 14-404 days) 233 
to lymphocyte recovery (defined by total lymphocyte count >1.0x106/ml) following AHSCT 234 
(See Figure 1). A high proportion (86%; n-25/29) of the MS patients in active follow-up 235 
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recovered lymphocyte counts around D56 with a median lymphocyte count of 1.56 (106 236 
cells/ml); Four patients remained lymphopenic at last follow up. 237 
 238 
All patients were stratified into following 3 groups according to peak rise/burden of EBV DNA-239 
aemia (copies/ml): <100,000 (<100k) copies/ml, 100,001-500,00 (100k-500k) copies/ml and 240 
>500,000 (>500k) copies/ml to identify any specific thresholds for clinically significant events 241 
related to rising EBV-R (Table 1). The majority of patients (76%) with rising EBV viral load 242 
>100k copies/ml were routinely screened by computed tomographic (CT) scans to assess for 243 
evidence of LPD, in line with our institutional policy. One third (34.5%) of patients developed 244 
peak EBV viraemia of >500k copies/ml. Eight patients (27.6%) developed symptomatic EBV-245 
R; defined as persistent fever, lymphadenopathy and/or B symptoms. Of these 8 patients, 246 
only 1 (12.5%) had a peak EBV viraemia <100kDNA copies/ml with the remaining 7 (87.5%) 247 
patients having a peak EBV viraemia of >500k copies/ml.  Three patients with rising EBV 248 
viraemia >500k copies/ml had findings consistent with probable LPD on CT imaging; 249 
however, none had definitive histological diagnosis. Three MS patients had worsening 250 
neurological symptoms concurrent with rising EBV viraemia >500k copies/ml and clonal 251 
gammopathy, as described below. 252 
 253 
Interestingly, we also observed frequent de novo monoclonal gammopathy (MG or M-protein) 254 
in 18 MS patients (62.4%) following rising EBV viraemia; the majority (n-16) of whom 255 
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developed IgG subtype and the remaining 2 developed IgA and IgM M-protein. Concerningly 256 
two of these patients developed clinically significant M-Protein burden; one patient with IgG 257 
Kappa M-protein of 45.6g/L developed hyper-viscosity and neurological symptoms mimicking 258 
MS relapse, requiring plasma exchange. Another patient developed significant lumbosacral 259 
radiculopathy with rising EBV-R and high IgM lambda M-protein (IgM 48.5g/L) (see 260 
supplementary case vignettes). Figure 2 highlights the association of neurological 261 
symptom onset following rising EBV viraemia (log copies), falling lymphocyte counts (x 262 
106/ml) with significant rise in M-protein (gm/lt) levels post AHSCT. A third patient developed 263 
painful lower limb paraesthesia following rising EBV viraemia >500k copies/ml, although did 264 
not have any M-protein detected. Their symptoms persisted at last follow up despite no 265 
evidence of MS related new disease activity. 266 
 267 
Six patients were treated with anti-CD20 antibody, rituximab (375mg/m2 weekly up to 4 268 
weeks), due to clinical severity of EBV reactivations and, leading to 1reduction in EBV viral 269 
load and concurrent improvement/resolution of EBV related symptoms. ROC curve analysis 270 
(Figure 3) confirmed EBV viraemia of >500k copies/ml correlated with high sensitivity 271 
(85.5%) and specificity (82.5%) (AUC-0.87; 95%CI-0.73-1.0; p-0.004) in predicting significant 272 
EBV related clinical events (evidence of LPD and/or neurological symptoms) that may require 273 
treatment with rituximab. The sensitivity dropped significantly on lower estimates for events 274 
below 500k copies/ml. 275 
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 276 
The median time to resolution of EBV viraemia post-rituximab was 21 days (IQR 19-124 days) 277 
in 5 patients with >500,000 k copies/ml (one patient was treated for late onset persistent 278 
symptomatic clonal gammopathy, despite fall in EBV levels). No significant adverse events 279 
were noted in the treated group. Nine patients had a persistent low level EBV viraemia 280 
detectable at last follow up. All patients who underwent AHSCT were alive as of April 2017.  281 
 282 
DISCUSSION: 283 
MS as an autoimmune disorder (AD) has is theorised to have generally similar underlying 284 
pathophysiological immune dysregulation mechanisms[18–22] relative to other chronic 285 
autoimmune conditions. Epstein-Barr virus (EBV) is increasingly implicated in the 286 
pathogenesis of MS by virtue of epidemiological and serological evidence, impaired CD8+ T 287 
cell immune responses to EBV and possible underlying genetic susceptibility for 288 
autoimmunity (with EBV encoded protein interactions), as recently described by Harley et al 289 
and others[1,23–25].  290 
 291 
Generally, EBV-R related LPD has been reported in both allogeneic (allo-HSCT) and solid 292 
organ transplants treated with immunosuppressive therapy, often with a significant impact  293 
on organ function and overall survival[26–30]. It is observed that reduced intensity allo-HSCT 294 
for malignant haematological conditions using alemtuzumab have a relatively lower overall 295 
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risk of LPD compared to ATG based treatments, possibly mediated by more effective pan-B 296 
& T cell lymphodepletion. In contrast, ATG primarily affects the T-cell repertoire with delayed 297 
EBV specific CD8+ T cell recovery[31]. Clinically significant endogenous viral infections 298 
including EBV following ATG conditioned AHSCT for severe ADs  such as Crohn’s disease 299 
and sSystemic sSclerosis is increasingly recognised, but the development of 300 
lymphoproliferative disorders (LPD) remains rare in these ADs[13,32,33].  Nash et al[32] 301 
concerningly reported 2 deaths (1 MS and 1 systemic sclerosis patient) from EBV related 302 
LPD in 56 ATG conditioned AHSCT for autoimmune diseases. Additionally, EBV associated 303 
haemophagocytosis in ATG-AHSCT for ADs have also been reported[34], with one resulting 304 
in death of the patient[35].  305 
 306 
Our report of suspected EBV related LPDs (~10%) in MS-AHSCT group is relatively higher 307 
than published reports with allo-HSCTs (4.5-7%)[36,37] and our own centre’s unpublished T-308 
cell depleted allo-HSCT experience (6.5%); possibly a reflection of underlying 309 
immunopathological state of MS itself[38]. This is further corroborated by the fact that similar 310 
LPD risk has not been observed in other ADds, e.g. Crohn’s disease,, treated with ATG -311 
AHSCT in this centre. Another example from ouour centre’s experience of in severe aplastic 312 
anaemiaa  (n-40), a type of AD causing severe bone marrow failure(n-40) treated  & treated 313 
with ATG/ciclosporin,n; only 52% (n-21/40)  patients developed EBV-R (unpublished data) 314 
and . nNone had LPD or required any treatment, supporting the notion that it may not just be 315 
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a specific ATG related problem.suggesting that the problem may not be ATG specific. 316 
 317 
Our study’s observation of significant persistent neurological events (with no evidence of new 318 
MS disease activity) associated with clonal gammopathy, suggest a potentially new clinical 319 
syndrome, described for the first time in ATG conditioned AHSCTs in MS and, possibly 320 
induced by clonal B cell dysregulation following EBV-R. It could be hypothesised that any 321 
remaining EBV infected latent B cells, which may still have survivedsurviving despite high 322 
doses of cyclophosphamide (given with mobilisation and conditioning in MS ASHCT)[8] and 323 
compounded by depletion of CD8+ T cells by ATG, may serve as potential source for EBV 324 
escape while interacting abnormally within the host immune micro-environment[39] and 325 
leading to rise in M-protein, LPD and neuro-inflammatory insults in some of the MS patients 326 
post AHSCT. Reports of lower incidence of EBV-R and LPD in another commonly used 327 
protocol for MS-AHSCT using BEAM-ATG (Ricardo Saccardi, Carregi University Hospital, 328 
Florence; personal communication) may reflect the greater myeloablative effect of BEAM 329 
chemotherapy which could further deplete the residual B cell pool and thus lower potential 330 
for EBV proliferation. It is plausible that dose of rATG is critical, given we have not seen 331 
similar reports from other centres where less rATG doses were given for MS-AHSCT (range 332 
between 5.0-6.5 mg/Kg; personal communication), but there seems to be some variability in 333 
prospective serial EBV monitoring in these patients. 334 
 335 
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The clinical threshold for EBV viral load as a significant risk factor for post-transplant LPD is 336 
widely debated. This study reports peak EBV viral load >500k copies/ml post AHSCT is 337 
significantly associated with probable LPD and neurological events in MS patients with high 338 
sensitivity (85.5%) and specificity (82.5%) (p-0.004) (Fig 3, ROC curve). Our ROC curve 339 
estimates are potentially limited by the relatively small number of events analysed but this 340 
has consistently been useful in our MS-AHSCT experience for predicting clinical events with 341 
high EBV load. Our EBV PCR assay has been validated against the recently defined standard 342 
WHO reference method (i.e. 10 copiesy/ml=10 IU/ml EBV DNA) [16] and thus this EBV 343 
threshold for pre-emptive treatment with Rituximab, can potentially be applied in relevant 344 
clinical context in other centres using similar validated essays. Rituximab treatment delivered 345 
good overall response in our symptomatic patients, with resolution of EBV related clinical 346 
symptoms and no subsequent viral or bacterial infections at last follow up. The role of 347 
prophylactic or pre-transplant rituximab in MS-AHSCT is also a potential area of interest in 348 
reducing risk of EBV-LPD in stem cell transplants as observed by Burns et al[36] and future 349 
randomised studies are required to investigate its potential benefit. 350 
 351 
Our study limitations include its retrospective nature and that no suspected LPD patients had 352 
histological confirmation, mainly related to patient refusal or technical difficulties. Seven MS 353 
patients were lost to follow up for EBV monitoring following discharge, which limits the 354 
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findings of this study. Additionally, our numbers were too small to identify any association of 355 
EBV related clinical events with previous DMT exposure in MS patients. 356 
 357 
In conclusion, symptomatic EBV reactivation increases risk of neurological sequelae and 358 
LPD in MS-AHSCT. Regular monitoring for rising EBV viraemia, as recommended by 359 
Snowden et al [10] and Muraro et al [11], and serum electrophoresis for M-protein should be 360 
considered mandated in the  first 3 months post-AHSCT for MS. and Wwe recommend 361 
persistent high EBV viraemia > 500k DNA copies/ml as potential trigger for consideration of 362 
pre-emptive anti-CD20 therapy and potentially reduce associated morbidity.  363 
 364 
 365 
 366 
 367 
 368 
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Table 1: Baseline patient characteristics and EBV related clinical events according to peak 527 
EBV DNA-aemia burden.  528 
 529 
Baseline characteristics (n-36) 
 
Patient Groups 
according to peak 
EBV DNA in 
copies/ml  
(n-29) 
0 - 100,000 
100,001 
- 
500,000 
>500,000 
Median age at time of AHSCT in years 
(range) 
43.5 
(36– 47) 
No of patients (%) 16 (55.2) 3 (10.3) 10 (34.5) 
Gender 
Male 
Female 
 
19 (52.8%) 
17 (47.2%) 
M-Protein (n) 11 0 7 
Disease Type (n; %) 
Relapsing Remitting MS 
Secondary Progressive MS 
Primary Progressive MS 
 
22 (61.1%) 
10 (27.8%) 
4 (11.1%) 
Median EBV DNA 
log value at peak 
(IQR) 
4.8 
(3.5-4.8) 
5.5 
(N/A) 
6.25 
(6.1-6.9) 
Median number of previous DMT 
(range) 
2 (0 – 6) 
Median number of 
prior DMTs 
2 3 2 
Previous use of high efficacy DMT (n) 
Natalizumab 
Alemtuzumab 
Both 
 
22 
8 
6 
Symptomatic EBV 
(n) 
1 0 7 
Median EDSS (range) 
6.0 
(2.5 – 8.0) 
LPD diagnosis 
(CT/Biopsy) (n) 
0 0 
3 
by CT alone 
Median follow up post AHSCT in days 
(range) 
436 
(188 – 785) 
Neuro/autoimmune 
complications (n) 
0 0 3 
No. of patients with prior EBV 
exposure (n; %) 
36 (100%) 
Treated with 
Rituximab (n) 
0 0 6 
No. of patients with detectable EBV 
post AHSCT (n; %) 
29 (80.5%) 
Confirmed EBV 
resolution at last 
follow up (n) 
7 2 7 
No. of patients lost to long term follow 
up (n; %) 
7 (19.5%) 
Detectable EBV DNA 
at last follow up (n) 
9 1 3 
Median Time to EBV detection post 
AHSCT in days (IQR) 
30 (23-46) 
Median time for EBV 
resolution (IQR in 
days) 
67 days 
(44-155) 
47 days 
(N/A) 
63 days 
(45 - 170) 
Median Time to peak EBV DNA levels 
in days (IQR) 
32 (31-53) 
Median Time to peak 
EBV DNA levels in 
days (IQR) 
40 days 
(25-85) 
30 days 
(N/A) 
39 days 
(32-43) 
 530 
Abbreviations: 531 
AHSCT- Autologous Haematopoietic Stem cell transplant; CT- computed tomography; DMT- 532 
Disease modifying therapy; EBV- Epstein Barr virus; EDSS- Kurtzke Expanded Disability 533 
Status Scale; IQR- Interquartile range; LPD- Lymphoproliferative disease; M-Protein: 534 
Monoclonal paraprotein or gammopathy; MS- Multiple Sclerosis 535 
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Figure Legends 536 
 537 
Figure 1: Trend of Lymphocyte count recovery following ATG in MS patients. 538 
 539 
Legend: This figure shows trends of lymphocyte count from baseline to recovery post 540 
AHSCT for MS patients. Majority of patients had normal baseline lymphocyte counts pre-541 
HSCT and became lymphopenic post ATG with counts recovering towards d+28 and >85% 542 
of patients recovered counts by d+56, with some overshooting from their baseline, possibly 543 
reflective of EBV related lymphoproliferation in some of these patients.  544 
 545 
AHSCT: Autologous Haematopoietic Stem Cell Transplantation; ATG: Anti-Thymocyte 546 
Globulin; d+: Days post AHSCT; MS: Multiple Sclerosis. 547 
 548 
 549 
Figure 2: Paraprotein, EBV & Lymphocyte trends in two MS patients with significant 550 
neurological sequelae post AHSCT. 551 
 552 
Legend: This figure demonstrates trends of EBV copies (log), paraprotein levels (g/lt) and 553 
Lymphocyte levels (counts x10^6/ml) in two MS patients with significant neurological 554 
symptoms following EBV reactivation. Both patients had significant EBV viraemia (log>5.2 555 
or >500,000 copy number) and developed significant paraproteinaemia, which was only 556 
noted after persistent unexplained neurological symptoms. The trend reversed following 557 
anti-CD20 (rituximab) therapy, with limited recovery in neurological symptoms. 558 
 559 
D: Days post AHSCT; EBV-R: Epstein Barr Virus reactivation; MS: Multiple sclerosis; 560 
AHSCT: Autologous Haematopoietic Stem Cell Transplants. 561 
 562 
 563 
Figure 3: ROC curve estimates for peak EBV viraemia levels and significant clinical 564 
events in MS post AHSCT. 565 
 566 
Legend: ROC curve demonstrating significant correlation between high EBV levels and 567 
clinical events (LPD & neurological events) in MS-AHSCT patients, with highest sensitivity 568 
and specificity noted with peak EBV viraemia of >500,000 copies/ml (p-0.0004). 569 
 570 
EBV: Epstein Barr Virus; LPD- Lymphoproliferative disorder; MS-AHSCT: Multiple Sclerosis 571 
patients treated with autologous haematopoietic stem cell transplants; ROC: receiver 572 
operating characteristics 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
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 582 
Figure 1: Trend of Lymphocyte count recovery following ATG conditioned AHSCT in 583 
MS patients. 584 
 585 
 586 
 587 
 588 
Abbreviations: 589 
AHSCT: Autologous Haematopoietic Stem Cell Transplantation; ATG: Anti-Thymocyte 590 
Globulin; d+: Days post AHSCT; MS: Multiple Sclerosis. 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
Lymphocyte count trends post ATG in MS-AHSCT 
Time (in days) since ATG in MS-AHSCT 
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Figure 2. Paraprotein, EBV & Lymphocyte trends in two MS patients with significant 600 
neurological sequelae post AHSCT 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
Abbreviations: 610 
D: Days post AHSCT; EBV-R: Epstein Barr Virus reactivation; MS: Multiple sclerosis; 611 
AHSCT: Autologous Haematopoietic Stem Cell Transplants. 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
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 622 
Figure 3: ROC curve estimates for peak EBV viraemia levels and significant clinical 623 
events in MS post AHSCT. 624 
 625 
 626 
 627 
Abbreviations: 628 
 629 
EBV: Epstein Barr Virus; LPD- Lymphoproliferative disorder; MS-AHSCT: Multiple Sclerosis 630 
patients treated with autologous haematopoietic stem cell transplants; ROC: receiver 631 
operating characteristics 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
EBV DNA in 
copies/ml  
Sensitivity Specificity 
0-50,000 100% 50% 
50,001-
100,000 
85.5% 60.1% 
100,001-
500,000 
85.5% 73.7% 
>500,001 85.5% 82% 
>700,000 71.4% 82% 
 
AUC-0.87 (95% CI: 0.73-1.0) AUC-0.87 (95% CI: 0.73-1.0); p-0.004 
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Abstract 111 
Introduction 112 
Autologous haematopoietic stem cell transplantation (AHSCT) with anti-thymocyte globulin 113 
(ATG) conditioning as treatment of active multiple sclerosis (MS) is rapidly increasing across 114 
Europe (EBMT registry data 2017). Clinically significant Epstein Barr virus reactivation (EBV-115 
R) following AHSCT with ATG for severe autoimmune conditions is an under-recognised 116 
complication relative to T-cell deplete transplants performed for haematological diseases. 117 
This retrospective study reports EBV-R associated significant clinical sequelae in MS patients 118 
undergoing AHSCT with rabbit ATG. 119 
Methods 120 
Retrospective data was analysed for 36 consecutive MS-AHSCT patients at Kings College 121 
Hospital, London. All patients routinely underwent weekly EBV DNA PCR monitoring and 122 
serum electrophoresis for monoclonal gammopathy (MG or M-protein). EBV-R with rising 123 
EBV viral load, M-protein and associated clinical sequelae were captured from clinical 124 
records. 125 
Results 126 
All patients had evidence of rising EBV DNA-emia, including 7 who were lost to long term 127 
follow-up, with a number of them developing high EBV viral load & associated 128 
lymphoproliferative disorder (LPD). Nearly 72% (n-18/29) developed de-novo MG, some with 129 
significant neurological consequences with high M-protein and EBV-R. Six patients required 130 
anti-CD20 therapy (rituximab) with complete resolution of EBV related symptoms. Receiver 131 
operating characteristics (ROC) estimated a peak EBV viraemia of >500,000 DNA copies/ml 132 
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correlated with high sensitivity (85.5%) & specificity (82.5%) (AUC-0.87; p-0.004) in 133 
predicting EBV-R related significant clinical events.  134 
Conclusion 135 
Symptomatic EBV reactivation increases risk of neurological sequelae and LPD in MS-136 
AHSCT. We recommend regular monitoring for EBV and serum electrophoresis for MG in 137 
MS patients in the first 3 months post AHSCT 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
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INTRODUCTION: 151 
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of the 152 
central nervous system[1]-[2], with  a relapsing-remitting (RRMS) presentation in the majority 153 
of patients at diagnosis.  Recovery from relapses may be complete or partial[3],[4]. After a 154 
variable period of time, people with RRMS may develop a more progressive disability 155 
accumulation with or without superimposed relapses; termed secondary progressive multiple 156 
sclerosis (SPMS). A minority experience progressive disability from the onset of disease, 157 
termed primary progressive multiple sclerosis (PPMS)[4]. A number of immunomodulatory 158 
disease modifying therapies (DMTs) are currently licensed for treatment of RRMS with an 159 
aim of reducing number of relapses and accrual of disability, although with variable 160 
efficacy[5]. Since 1996, Autologous Hematopoietic Stem Cell Transplantation (AHSCT) has 161 
been a novel approach for MS management, using immunoablation followed by 162 
immunomodulation mechanisms, with evidence of significant suppression of inflammatory 163 
activity and qualitative changes in the reconstituted immune system (immune reset theory)[6–164 
8]. AHSCT appears most effective for MS patients with evidence of inflammatory activity on 165 
MRI, younger age, a shorter disease duration, low to moderate disability levels (Expanded 166 
Disability Status Scale [EDSS] <6 or up to 6.5 if recent progression) and failure of at least 1 167 
highly active DMT (natalizumab or alemtuzumab) with no significant comorbidities[9–11]. 168 
Recently reported preliminary results of randomised MIST study[12] found AHSCT to be 169 
superior to standard  disease modifying therapy (DMT) for RRMS with respect to both 170 
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treatment failure and disability progression. 171 
 172 
However, risk of subsequent rise in opportunistic infections following such 173 
immunosuppressive therapies remain a potential concern[13]. MS patients undergoing 174 
AHSCT have often been exposed to a number of immunomodulating DMTs; the addition of 175 
immunosuppressive rabbit anti-thymocyte globulin (rATG) to their conditioning regimen may 176 
confer a higher risk of viral reactivation in these patients. The number of AHSCTs performed 177 
for MS is rising significantly in Europe[14] and as more centres perform AHSCT for this 178 
indication, it is increasingly important to recognise the unique problems faced by these 179 
patients post AHSCT. This retrospective study reports for the first time, EBV-R associated 180 
neurological sequelae and lymphoproliferative disorder (LPD) in MS patients undergoing 181 
rATG conditioned AHSCT in our centre. 182 
 183 
METHODS 184 
Patients and procedures 185 
Data was collected retrospectively on 36 consecutive MS patients undergoing AHSCT 186 
between February 2012 and February 2017 at Kings College Hospital, London. Peripheral 187 
blood stem cells were collected following standard mobilisation strategy consisting of 188 
cyclophosphamide 4g/m2 over 2 days and granulocyte colony-stimulating factor for 7 days. 189 
Thirty-five (97%) patients were conditioned using standard protocol of cyclophosphamide 190 
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(50mg/kg for 4 days) and rATG (2.5mg/kg/day for 3 days) for in-vivo lymphodepletion 191 
followed by stem cell infusion. One patient was conditioned with 192 
carmustine/etoposide/cytarabine/melphalan regimen along with an equivalent dose of rATG 193 
(BEAM-ATG) prior to stem cell infusion. The median CD34 stem cell dose returned was 7.17 194 
x10^6/kg (range 4.0-17.1x10^6/kg).  195 
 196 
Prior exposure to EBV was assessed by serological evidence (EBV viral capsid antigen; VCA 197 
IgG).  EBV DNA load monitoring was performed on whole blood samples by standardised 198 
quantitative real-time polymerase chain reaction (RT-PCR) using Rotor-GeneTM (Qiagen) 199 
assay of EBV BZLF1 DNA. This assay was adapted from our published assay using 200 
LightCycler (Roche)[15] and since been validated against the recently published WHO 201 
standard, with our lab’s EBV DNA quantification of 10 copies/ml considered equivalent to 10 202 
IU/ml DNA reported with the WHO reference method[16]. EBV-R was defined as rising EBV 203 
DNA load of >10 copies/millilitre (ml) detected on two consecutive tests based on our assay 204 
sensitivity. Symptomatic EBV-R was captured by peak blood EBV DNA load, presence of B 205 
symptoms (defined by presence of either unexplained weight loss, recurrent fever, night 206 
sweats); which was in-turn defined by clinical, radiological and/or histological evidence based 207 
on recent ECIL-6 guidelines[17]. In addition, significant ‘clinical events’ were also defined as 208 
new & persistent organ dysfunction (e.g. neurological events) temporally associated with 209 
rising EBV viraemia in MS patients. Serum protein electrophoresis was routinely tested 210 
around 3 months post HSCT as part of our institutional practice, with immunoglobulin 211 
subclasses identified by immunofixation electrophoresis. Patient outcomes were assessed at 212 
last follow up as of April 2017.  213 
 214 
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Statistics 215 
The database of transplants and outcomes was built in Microsoft Excel 2016 and statistical 216 
analyses were performed using IBM SPSS Statistics version 24.0. Patient characteristics are 217 
presented as medians (with inter-quartile ranges; IQR) for data with non-normal distribution. 218 
Comparisons of baseline characteristics used Mann-Whitney U test, Fisher’s exact test, or 219 
Chi-squared test for trend as appropriate. Receiver Operating characteristics (ROC) curve 220 
was obtained correlating LPD and clonal gammopathy associated clinical events with rising 221 
EBV viraemia (copies/ml). 222 
 223 
RESULTS 224 
Baseline characteristics are presented in Table 1.  Most MS patients (88.9%) had RRMS 225 
phenotype with median of 2 (range 0-3) DMTs prior to AHSCT. Twenty-two MS patients had 226 
prior exposure to natalizumab and 7 were treated with Alemtuzumab (6 patients received 227 
both). All 36 (100%) MS patients were serologically positive for EBV VCA IgG pre-treatment, 228 
indicating prior EBV exposure and had detectable EBV DNA post-AHSCT. Seven MS 229 
patients were lost to long-term follow up for EBV monitoring.  The median time to first EBV 230 
DNA detection post-transplant was 30 days (IQR 23-46 days). EBV DNA levels peaked at a 231 
median of 32 days post-transplant (IQR 31-53 days). All MS patients had normal baseline 232 
lymphocyte counts (median) pre-HSCT with a median time of 46 days (range 14-404 days) 233 
to lymphocyte recovery (defined by total lymphocyte count >1.0x106/ml) following AHSCT 234 
(See Figure 1). A high proportion (86%; n-25/29) of the MS patients in active follow-up 235 
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recovered lymphocyte counts around D56 with a median lymphocyte count of 1.56 (106 236 
cells/ml); Four patients remained lymphopenic at last follow up. 237 
 238 
All patients were stratified into following 3 groups according to peak rise/burden of EBV DNA-239 
aemia (copies/ml): <100,000 (<100k) copies/ml, 100,001-500,00 (100k-500k) copies/ml and 240 
>500,000 (>500k) copies/ml to identify any specific thresholds for clinically significant events 241 
related to rising EBV-R (Table 1). The majority of patients (76%) with rising EBV viral load 242 
>100k copies/ml were routinely screened by computed tomographic (CT) scans to assess for 243 
evidence of LPD, in line with our institutional policy. One third (34.5%) of patients developed 244 
peak EBV viraemia of >500k copies/ml. Eight patients (27.6%) developed symptomatic EBV-245 
R; defined as persistent fever, lymphadenopathy and/or B symptoms. Of these 8 patients, 246 
only 1 (12.5%) had a peak EBV viraemia <100kDNA copies/ml with the remaining 7 (87.5%) 247 
patients having a peak EBV viraemia of >500k copies/ml.  Three patients with rising EBV 248 
viraemia >500k copies/ml had findings consistent with probable LPD on CT imaging; 249 
however, none had definitive histological diagnosis. Three MS patients had worsening 250 
neurological symptoms concurrent with rising EBV viraemia >500k copies/ml and clonal 251 
gammopathy, as described below. 252 
 253 
Interestingly, we also observed frequent de novo monoclonal gammopathy (MG or M-protein) 254 
in 18 MS patients (62.4%) following rising EBV viraemia; the majority (n-16) of whom 255 
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developed IgG subtype and the remaining 2 developed IgA and IgM M-protein. Concerningly 256 
two of these patients developed clinically significant M-Protein burden; one patient with IgG 257 
Kappa M-protein of 45.6g/L developed hyper-viscosity and neurological symptoms mimicking 258 
MS relapse, requiring plasma exchange. Another patient developed significant lumbosacral 259 
radiculopathy with rising EBV-R and high IgM lambda M-protein (IgM 48.5g/L) (see 260 
supplementary case vignettes). Figure 2 highlights the association of neurological 261 
symptom onset following rising EBV viraemia (log copies), falling lymphocyte counts (x 262 
106/ml) with significant rise in M-protein (gm/lt) levels post AHSCT. A third patient developed 263 
painful lower limb paraesthesia following rising EBV viraemia >500k copies/ml, although did 264 
not have any M-protein detected. Their symptoms persisted at last follow up despite no 265 
evidence of MS related new disease activity. 266 
 267 
Six patients were treated with anti-CD20 antibody, rituximab (375mg/m2 weekly up to 4 268 
weeks), due to clinical severity of EBV reactivations and leading to reduction in EBV viral 269 
load and concurrent improvement/resolution of EBV related symptoms. ROC curve analysis 270 
(Figure 3) confirmed EBV viraemia of >500k copies/ml correlated with high sensitivity 271 
(85.5%) and specificity (82.5%) (AUC-0.87; 95%CI-0.73-1.0; p-0.004) in predicting significant 272 
EBV related clinical events (evidence of LPD and/or neurological symptoms) that may require 273 
treatment with rituximab. The sensitivity dropped significantly on lower estimates for events 274 
below 500k copies/ml. 275 
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 276 
The median time to resolution of EBV viraemia post-rituximab was 21 days (IQR 19-124 days) 277 
in 5 patients with >500k copies/ml (one patient was treated for late onset persistent 278 
symptomatic clonal gammopathy, despite fall in EBV levels). No significant adverse events 279 
were noted in the treated group. Nine patients had a persistent low level EBV viraemia 280 
detectable at last follow up. All patients who underwent AHSCT were alive as of April 2017.  281 
 282 
DISCUSSION: 283 
MS as an autoimmune disorder (AD) is theorised to have generally similar underlying 284 
pathophysiological immune dysregulation mechanisms[18–22] relative to other chronic 285 
autoimmune conditions. Epstein-Barr virus (EBV) is increasingly implicated in the 286 
pathogenesis of MS by virtue of epidemiological and serological evidence, impaired CD8+ T 287 
cell immune responses to EBV and possible underlying genetic susceptibility for 288 
autoimmunity (with EBV encoded protein interactions), as recently described by Harley et al 289 
and others[1,23–25].  290 
 291 
Generally, EBV-R related LPD has been reported in both allogeneic (allo-HSCT) and solid 292 
organ transplants treated with immunosuppressive therapy, often with a significant impact  293 
on organ function and overall survival[26–30]. It is observed that reduced intensity allo-HSCT 294 
for malignant haematological conditions using alemtuzumab have a relatively lower overall 295 
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risk of LPD compared to ATG based treatments, possibly mediated by more effective pan-B 296 
& T cell lymphodepletion. In contrast, ATG primarily affects the T-cell repertoire with delayed 297 
EBV specific CD8+ T cell recovery[31]. Clinically significant endogenous viral infections 298 
including EBV following ATG conditioned AHSCT for severe ADs  such as Crohn’s disease 299 
and systemic sclerosis is increasingly recognised, but the development of lymphoproliferative 300 
disorders (LPD) remains rare in these ADs[13,32,33].  Nash et al[32] concerningly reported 301 
2 deaths (1 MS and 1 systemic sclerosis patient) from EBV related LPD in 56 ATG 302 
conditioned AHSCT for autoimmune diseases. Additionally, EBV associated 303 
haemophagocytosis in ATG-AHSCT for ADs have also been reported[34], with one resulting 304 
in death of the patient[35].  305 
 306 
Our report of suspected EBV related LPDs (~10%) in MS-AHSCT group is relatively higher 307 
than published reports with allo-HSCTs (4.5-7%)[36,37] and our own centre’s unpublished T-308 
cell depleted allo-HSCT experience (6.5%); possibly a reflection of underlying 309 
immunopathological state of MS itself[38]. This is further corroborated by the fact that similar 310 
LPD risk has not been observed in other ADs, e.g. Crohn’s disease, treated with ATG -311 
AHSCT in this centre. Another example from our centre’s experience of severe aplastic 312 
anaemia (n-40) treated with ATG/ciclosporin, only 52% (n-21/40) developed EBV-R 313 
(unpublished data) and none had LPD or required any treatment, suggesting that the problem 314 
may not be ATG specific. 315 
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 316 
Our study’s observation of significant persistent neurological events (with no evidence of new 317 
MS disease activity) associated with clonal gammopathy suggest a potentially new clinical 318 
syndrome, described for the first time in ATG conditioned AHSCTs in MS and possibly 319 
induced by clonal B cell dysregulation following EBV-R. It could be hypothesised that any 320 
remaining EBV infected latent B cells, surviving despite high doses of cyclophosphamide 321 
(given with mobilisation and conditioning in MS ASHCT)[8] and compounded by depletion of 322 
CD8+ T cells by ATG, may serve as potential source for EBV escape while interacting 323 
abnormally within the host immune micro-environment[39] and leading to rise in M-protein, 324 
LPD and neuro-inflammatory insults in some of the MS patients post AHSCT. Reports of 325 
lower incidence of EBV-R and LPD in another commonly used protocol for MS-AHSCT using 326 
BEAM-ATG (Ricardo Saccardi, Carregi University Hospital, Florence; personal 327 
communication) may reflect the greater myeloablative effect of BEAM chemotherapy which 328 
could further deplete the residual B cell pool and thus lower potential for EBV proliferation. It 329 
is plausible that dose of rATG is critical, given we have not seen similar reports from other 330 
centres where less rATG doses were given for MS-AHSCT (range between 5.0-6.5 mg/Kg; 331 
personal communication) but there seems to be some variability in prospective serial EBV 332 
monitoring in these patients. 333 
 334 
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The clinical threshold for EBV viral load as a significant risk factor for post-transplant LPD is 335 
widely debated. This study reports peak EBV viral load >500k copies/ml post AHSCT is 336 
significantly associated with probable LPD and neurological events in MS patients with high 337 
sensitivity (85.5%) and specificity (82.5%) (p-0.004) (Fig 3, ROC curve). Our ROC curve 338 
estimates are potentially limited by the relatively small number of events analysed but this 339 
has consistently been useful in our MS-AHSCT experience for predicting clinical events with 340 
high EBV load. Our EBV PCR assay has been validated against the recently defined standard 341 
WHO reference method (i.e. 10 copies/ml=10 IU/ml EBV DNA) [16] and thus this EBV 342 
threshold for pre-emptive treatment with Rituximab, can potentially be applied in relevant 343 
clinical context in other centres using similar validated essays. Rituximab treatment delivered 344 
good overall response in our symptomatic patients, with resolution of EBV related clinical 345 
symptoms and no subsequent viral or bacterial infections at last follow up. The role of 346 
prophylactic or pre-transplant rituximab in MS-AHSCT is also a potential area of interest in 347 
reducing risk of EBV-LPD in stem cell transplants as observed by Burns et al[36] and future 348 
randomised studies are required to investigate its potential benefit. 349 
 350 
Our study limitations include its retrospective nature and that no suspected LPD patients had 351 
histological confirmation, mainly related to patient refusal or technical difficulties. Seven MS 352 
patients were lost to follow up for EBV monitoring following discharge, which limits the 353 
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findings of this study. Additionally, our numbers were too small to identify any association of 354 
EBV related clinical events with previous DMT exposure in MS patients. 355 
 356 
In conclusion, symptomatic EBV reactivation increases risk of neurological sequelae and 357 
LPD in MS-AHSCT. Regular monitoring for rising EBV viraemia, as recommended by 358 
Snowden et al [10] and Muraro et al [11], and serum electrophoresis for M-protein should be 359 
considered in the  first 3 months post-AHSCT for MS. We recommend persistent high EBV 360 
viraemia > 500k DNA copies/ml as potential trigger for consideration of pre-emptive anti-361 
CD20 therapy and potentially reduce associated morbidity.  362 
 363 
 364 
 365 
 366 
 367 
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Table 1: Baseline patient characteristics and EBV related clinical events according to peak 526 
EBV DNA-aemia burden.  527 
 528 
Baseline characteristics (n-36) 
 
Patient Groups 
according to peak 
EBV DNA in 
copies/ml  
(n-29) 
0 - 100,000 
100,001 
- 
500,000 
>500,000 
Median age at time of AHSCT in years 
(range) 
43.5 
(36– 47) 
No of patients (%) 16 (55.2) 3 (10.3) 10 (34.5) 
Gender 
Male 
Female 
 
19 (52.8%) 
17 (47.2%) 
M-Protein (n) 11 0 7 
Disease Type (n; %) 
Relapsing Remitting MS 
Secondary Progressive MS 
Primary Progressive MS 
 
22 (61.1%) 
10 (27.8%) 
4 (11.1%) 
Median EBV DNA 
log value at peak 
(IQR) 
4.8 
(3.5-4.8) 
5.5 
(N/A) 
6.25 
(6.1-6.9) 
Median number of previous DMT 
(range) 
2 (0 – 6) 
Median number of 
prior DMTs 
2 3 2 
Previous use of high efficacy DMT (n) 
Natalizumab 
Alemtuzumab 
Both 
 
22 
8 
6 
Symptomatic EBV 
(n) 
1 0 7 
Median EDSS (range) 
6.0 
(2.5 – 8.0) 
LPD diagnosis 
(CT/Biopsy) (n) 
0 0 
3 
by CT alone 
Median follow up post AHSCT in days 
(range) 
436 
(188 – 785) 
Neuro/autoimmune 
complications (n) 
0 0 3 
No. of patients with prior EBV 
exposure (n; %) 
36 (100%) 
Treated with 
Rituximab (n) 
0 0 6 
No. of patients with detectable EBV 
post AHSCT (n; %) 
29 (80.5%) 
Confirmed EBV 
resolution at last 
follow up (n) 
7 2 7 
No. of patients lost to long term follow 
up (n; %) 
7 (19.5%) 
Detectable EBV DNA 
at last follow up (n) 
9 1 3 
Median Time to EBV detection post 
AHSCT in days (IQR) 
30 (23-46) 
Median time for EBV 
resolution (IQR in 
days) 
67 days 
(44-155) 
47 days 
(N/A) 
63 days 
(45 - 170) 
Median Time to peak EBV DNA levels 
in days (IQR) 
32 (31-53) 
Median Time to peak 
EBV DNA levels in 
days (IQR) 
40 days 
(25-85) 
30 days 
(N/A) 
39 days 
(32-43) 
 529 
Abbreviations: 530 
AHSCT- Autologous Haematopoietic Stem cell transplant; CT- computed tomography; DMT- 531 
Disease modifying therapy; EBV- Epstein Barr virus; EDSS- Kurtzke Expanded Disability 532 
Status Scale; IQR- Interquartile range; LPD- Lymphoproliferative disease; M-Protein: 533 
Monoclonal paraprotein or gammopathy; MS- Multiple Sclerosis 534 
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Figure Legends 535 
 536 
Figure 1: Trend of Lymphocyte count recovery following ATG in MS patients. 537 
 538 
Legend: This figure shows trends of lymphocyte count from baseline to recovery post 539 
AHSCT for MS patients. Majority of patients had normal baseline lymphocyte counts pre-540 
HSCT and became lymphopenic post ATG with counts recovering towards d+28 and >85% 541 
of patients recovered counts by d+56, with some overshooting from their baseline, possibly 542 
reflective of EBV related lymphoproliferation in some of these patients.  543 
 544 
AHSCT: Autologous Haematopoietic Stem Cell Transplantation; ATG: Anti-Thymocyte 545 
Globulin; d+: Days post AHSCT; MS: Multiple Sclerosis. 546 
 547 
 548 
Figure 2: Paraprotein, EBV & Lymphocyte trends in two MS patients with significant 549 
neurological sequelae post AHSCT. 550 
 551 
Legend: This figure demonstrates trends of EBV copies (log), paraprotein levels (g/lt) and 552 
Lymphocyte levels (counts x10^6/ml) in two MS patients with significant neurological 553 
symptoms following EBV reactivation. Both patients had significant EBV viraemia (log>5.2 554 
or >500,000 copy number) and developed significant paraproteinaemia, which was only 555 
noted after persistent unexplained neurological symptoms. The trend reversed following 556 
anti-CD20 (rituximab) therapy, with limited recovery in neurological symptoms. 557 
 558 
D: Days post AHSCT; EBV-R: Epstein Barr Virus reactivation; MS: Multiple sclerosis; 559 
AHSCT: Autologous Haematopoietic Stem Cell Transplants. 560 
 561 
 562 
Figure 3: ROC curve estimates for peak EBV viraemia levels and significant clinical 563 
events in MS post AHSCT. 564 
 565 
Legend: ROC curve demonstrating significant correlation between high EBV levels and 566 
clinical events (LPD & neurological events) in MS-AHSCT patients, with highest sensitivity 567 
and specificity noted with peak EBV viraemia of >500,000 copies/ml (p-0.0004). 568 
 569 
EBV: Epstein Barr Virus; LPD- Lymphoproliferative disorder; MS-AHSCT: Multiple Sclerosis 570 
patients treated with autologous haematopoietic stem cell transplants; ROC: receiver 571 
operating characteristics 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
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 581 
Figure 1: Trend of Lymphocyte count recovery following ATG conditioned AHSCT in 582 
MS patients. 583 
 584 
 585 
 586 
 587 
Abbreviations: 588 
AHSCT: Autologous Haematopoietic Stem Cell Transplantation; ATG: Anti-Thymocyte 589 
Globulin; d+: Days post AHSCT; MS: Multiple Sclerosis. 590 
 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
Lymphocyte count trends post ATG in MS-AHSCT 
Time (in days) since ATG in MS-AHSCT 
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Figure 2. Paraprotein, EBV & Lymphocyte trends in two MS patients with significant 599 
neurological sequelae post AHSCT 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
Abbreviations: 609 
D: Days post AHSCT; EBV-R: Epstein Barr Virus reactivation; MS: Multiple sclerosis; 610 
AHSCT: Autologous Haematopoietic Stem Cell Transplants. 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
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 621 
Figure 3: ROC curve estimates for peak EBV viraemia levels and significant clinical 622 
events in MS post AHSCT. 623 
 624 
 625 
 626 
Abbreviations: 627 
 628 
EBV: Epstein Barr Virus; LPD- Lymphoproliferative disorder; MS-AHSCT: Multiple Sclerosis 629 
patients treated with autologous haematopoietic stem cell transplants; ROC: receiver 630 
operating characteristics 631 
 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
EBV DNA in 
copies/ml  
Sensitivity Specificity 
0-50,000 100% 50% 
50,001-
100,000 
85.5% 60.1% 
100,001-
500,000 
85.5% 73.7% 
>500,001 85.5% 82% 
>700,000 71.4% 82% 
 
AUC-0.87 (95% CI: 0.73-1.0) AUC-0.87 (95% CI: 0.73-1.0); p-0.004 
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